European Society of Urogenital Radiology guidelines on administering contrast media
Abstract
The European Society of Urogenital Radiology is committed to improving knowledge and understanding about contrast media. There seemed to be little agreement about the best approach for the prevention of contrast medium-induced nephrotoxicity or generalized adverse reactions and the use of intravascular contrast media in diabetic patients receiving metformin. There was also concern that there might be discrepancies between current practice and published recommendations on these subjects. The Contrast Media Safety Committee of the European Society of Urogenital Radiology has produced practical guidelines on these important topics based on wide consensus and extensive review of the literature. The details of the guidelines are presented in this review.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.